Literature DB >> 32595766

The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.

Saptarshi Bhattacharya1, Sanjay Kalra2, Deep Dutta3, Deepak Khandelwal4, Rajiv Singla5.   

Abstract

The anterior and posterior hypophyseal hormones alter glucose metabolism in health and disease. Secondary diabetes may occur due to hypersecretion of anterior pituitary hormones like adrenocorticotrophic hormone in Cushing's disease and growth hormone in acromegaly. Other hormones like prolactin, gonadotropins, oxytocin and vasopressin, though not overtly associated with causation of diabetes, have important physiological role in maintaining glucose homeostasis. Hypoglycaemia is not an unusual occurrence in hypopituitarism. Many of the medications that are used for treatment of hypophyseal diseases alter glucose metabolism. Agents like pasireotide should be used with caution in the setting of diabetes, whereas pegvisomant should be given preference. Diabetes mellitus itself, on the other hand, can alter the functioning of hypothalamic pituitary axis; this is documented in both type 1 and type 2 diabetes. This review focuses on the clinically relevant interplay of hypophyseal hormones and glucose homeostasis. The authors define 'hypophyseo-vigilance' as an approach which keeps the bidirectional, multifaceted interactions between the pituitary and glucose metabolism in mind while managing diabetes and pituitary disease. © Touch Medical Media 2020.

Entities:  

Keywords:  Cushing’s disease; Diabetes mellitus; acromegaly; hypogonadism; hypophysis; pituitary

Year:  2019        PMID: 32595766      PMCID: PMC7308101          DOI: 10.17925/EE.2020.16.1.25

Source DB:  PubMed          Journal:  Eur Endocrinol        ISSN: 1758-3772


  108 in total

1.  Predictors of morbidity and mortality in acromegaly: an Italian survey.

Authors:  M Arosio; G Reimondo; E Malchiodi; P Berchialla; A Borraccino; L De Marinis; R Pivonello; S Grottoli; M Losa; S Cannavò; F Minuto; M Montini; M Bondanelli; E De Menis; C Martini; G Angeletti; A Velardo; A Peri; M Faustini-Fustini; P Tita; F Pigliaru; G Borretta; C Scaroni; N Bazzoni; A Bianchi; M Appetecchia; F Cavagnini; G Lombardi; E Ghigo; P Beck-Peccoz; A Colao; M Terzolo
Journal:  Eur J Endocrinol       Date:  2012-05-17       Impact factor: 6.664

Review 2.  Combination treatment with somatostatin analogues and pegvisomant in acromegaly.

Authors:  S J C M M Neggers; A J van der Lely
Journal:  Growth Horm IGF Res       Date:  2011-04-16       Impact factor: 2.372

3.  Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.

Authors:  Christina A Hedman; Jan Frystyk; Torbjörn Lindström; Per Oskarsson; Hans J Arnqvist
Journal:  Clin Endocrinol (Oxf)       Date:  2013-08-17       Impact factor: 3.478

4.  The role of arginine vasopressin in diabetes-associated increase in glucagon secretion.

Authors:  Sirintorn Yibchok-anun; Ehab A Abu-Basha; Cheng-Yu Yao; Wara Panichkriangkrai; Walter H Hsu
Journal:  Regul Pept       Date:  2004-11-15

5.  The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.

Authors:  Joost van der Hoek; Aart-Jan van der Lelij; Richard A Feelders; Wouter W de Herder; Piet Uitterlinden; Kwai W Poon; Viktor Boerlin; Ian Lewis; Tillmann Krahnke; Leo J Hofland; Steven W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  2005-08       Impact factor: 3.478

6.  Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.

Authors:  Robert R Henry; Theodore P Ciaraldi; Debra Armstrong; Paivi Burke; Monica Ligueros-Saylan; Sunder Mudaliar
Journal:  J Clin Endocrinol Metab       Date:  2013-06-03       Impact factor: 5.958

Review 7.  Growth hormone and insulin-like growth factor-I axis in type 1 diabetes.

Authors:  Bimota Nambam; Desmond Schatz
Journal:  Growth Horm IGF Res       Date:  2017-12-13       Impact factor: 2.372

Review 8.  Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.

Authors:  Ralph A Defronzo
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

9.  Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Authors:  Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers
Journal:  Endocr Relat Cancer       Date:  2017-07-21       Impact factor: 5.678

Review 10.  Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment.

Authors:  Francesco Ferraù; Adriana Albani; Alessandro Ciresi; Carla Giordano; Salvatore Cannavò
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-06       Impact factor: 5.555

View more
  1 in total

Review 1.  The Role of HIV Infection in the Pathophysiology of Gestational Diabetes Mellitus and Hypertensive Disorders of Pregnancy.

Authors:  Wendy N Phoswa
Journal:  Front Cardiovasc Med       Date:  2021-05-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.